NEOGENOMICS INC 8-K

What Happened
NeoGenomics, Inc. (NEO) filed an 8-K reporting that the Board accepted the resignation of director Dr. Alison L. Hannah effective December 31, 2025, and appointed Jack Kenny to the Board effective January 1, 2026. The company issued a press release on December 29, 2025 announcing the change.

Key Details

• Dr. Alison L. Hannah resigned from the Board effective December 31, 2025 (resignation accepted December 23, 2025).
• Jack Kenny was appointed to the Board effective January 1, 2026 and will serve until the 2026 annual meeting of stockholders (or until his earlier resignation or removal).
• Mr. Kenny will receive director compensation consistent with NeoGenomics’ previously disclosed director compensation program (see the company’s 2025 proxy).
• The company reported no related-party transactions involving Mr. Kenny requiring disclosure under Item 404(a) of Regulation S-K. A press release dated December 29, 2025 was attached as Exhibit 99.1 to the 8-K.

Why It Matters
This filing reflects a routine change in board composition—important for investors watching corporate governance and board expertise. The appointment is temporary until the next annual meeting and does not involve disclosed related-party transactions or special compensation beyond the standard director program. Investors who track board changes for oversight, strategy or governance reasons should note the names, effective dates, and that the company publicly disclosed the change via press release.